Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).

ABSTRACT:

Background

An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF.

Methods and results

We randomly assigned 60 patients with reduced left ventricular ejection fraction (<50%) and elevated C-reactive protein levels (>2 mg/L), within 14 days of hospital discharge, to daily subcutaneous injections with anakinra 100 mg for 2 weeks, 12 weeks, or placebo. Patients underwent measurement of peak oxygen consumption (Vo₂ [mL/kg per minute]) and ventilatory efficiency (the VE/Vco₂ slope). Treatment with anakinra did

SUBMITTER: Van Tassell BW 

PROVIDER: S-EPMC5699505 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature